APA

Cole G. D., Patel S. J., Zaman N., Barron A. J., Raphael C. E., Mayet J. & Francis D. P. (20151102). "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients?. : JACC. Heart failure.

Chicago

Cole Graham D, Patel Sheetal J, Zaman Nabeela, Barron Anthony J, Raphael Claire E, Mayet Jamil and Francis Darrel P. 20151102. "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients?. : JACC. Heart failure.

Harvard

Cole G. D., Patel S. J., Zaman N., Barron A. J., Raphael C. E., Mayet J. and Francis D. P. (20151102). "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients?. : JACC. Heart failure.

MLA

Cole Graham D, Patel Sheetal J, Zaman Nabeela, Barron Anthony J, Raphael Claire E, Mayet Jamil and Francis Darrel P. "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients?. : JACC. Heart failure. 20151102.